Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
Lin LS, Ha S, Ball RG, Tsou NN, Castonguay LA, Doss GA, Fong TM, Shen CP, Xiao JC, Goulet MT, Hagmann WK, J Med Chem, 2008 Apr 10 - link

Evaluation of docking/scoring approaches: a comparative study based on MMP3 inhibitors.
Ha S, Andreani R, Robbins A, Muegge I, J Comput Aided Mol Des, 2000 Jul - link